Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome - 20/04/20
Doi : 10.1016/j.jbspin.2020.03.011
Luca Quartuccio a, ⁎ 
, Luca Semerano b, c, d, Maurizio Benucci e, Marie-Christophe Boissier b, c, d, Salvatore De Vita a
, Luca Semerano b, c, d, Maurizio Benucci e, Marie-Christophe Boissier b, c, d, Salvatore De Vita a a Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy
b Université Sorbonne Paris Nord, Li2P, Bobigny, France
c Inserm U1125, Bobigny, France
d Assistance Publique-Hôpitaux de Paris, GH HUPSSD, Rheumatology Department, Bobigny, France
e Rheumatology Unit, S. Giovanni di Dio Hospital, Florence, Italy
⁎Corresponding author. Clinic of Rheumatology, ASUFC, Department of Medicine (DAME), University of Udine, Udine, Italy.Clinic of Rheumatology, ASUFC, Department of Medicine (DAME), University of UdineUdineItaly
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Keywords : COVID-19, Coronavirus, SARS, Cytokine, IL-6
El texto completo de este artículo está disponible en PDF.
Esquema
© 2020
Société française de rhumatologie. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 87 - N° 3
P. 191-193 - mai 2020 Regresar al número
Artículo precedente
- Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases
- Christophe Richez, Estibaliz Lazaro, Maël Lemoine, Marie-Elise Truchetet, Thierry Schaeverbeke
- Old and new antirheumatic drugs for the treatment of COVID-19
- Maurizio Benucci, Arianna Damiani, Maria Infantino, Mariangela Manfredi, Luca Quartuccio
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.